Inner Mongolia Furui Medical Science Co Ltd
SZSE:300049
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
I
|
Inner Mongolia Furui Medical Science Co Ltd
SZSE:300049
|
17.7B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Inner Mongolia Furui Medical Science Co Ltd
Glance View
In the vast expanse of the healthcare landscape, Inner Mongolia Furui Medical Science Co., Ltd. has carved its niche by melding traditional Chinese medical wisdom with contemporary scientific advancements. Founded in the milieu of China's rich cultural heritage in Inner Mongolia, the company has emerged as a pivotal player in the pharmaceutical and biotechnology sectors. It specializes in the research, development, production, and sale of heparin products. Heparin, an anticoagulant drug crucial in preventing and treating blood clots, has been the cornerstone of Furui Medical's success, establishing them as a key supplier in both domestic and international markets. By leveraging China's comprehensive supply chain and stringent quality control measures, Furui has ensured its products meet the demanding standards of healthcare providers worldwide. At the heart of Furui Medical's business model is a well-oiled system that not only focuses on enhancing product efficacy but also strives for innovation in its production processes. The company has invested significantly in building state-of-the-art manufacturing facilities and a robust R&D department, which allow it to maintain a competitive edge in the biopharmaceutical domain. This focus on technological enhancement and adherence to international quality standards facilitates Furui Medical's penetration into global markets, particularly in Europe and North America. Additionally, their strategic partnerships and expansive distribution networks help them capitalize on emerging opportunities in the global anticoagulant market. Through this blend of tradition and modernity, Furui Medical not only contributes to the healing arts but also ensures sustainable business growth.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Inner Mongolia Furui Medical Science Co Ltd is 8.4%, which is below its 3-year median of 8.9%.
Over the last 3 years, Inner Mongolia Furui Medical Science Co Ltd’s Net Margin has decreased from 9.6% to 8.4%. During this period, it reached a low of 6.3% on Jun 30, 2025 and a high of 10.6% on Mar 31, 2024.